Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
05/2009
05/19/2009US7534888 Oxycodone polymorphs
05/19/2009US7534887 Thiazoline derivative and use of the same
05/19/2009US7534884 Preparation of pharmaceutical salts
05/19/2009US7534870 Stable pharmaceutical composition comprising erythropoietin
05/19/2009US7534863 Leucine-based motifs and enhanced biological persistence of clostridial neurotoxins
05/19/2009US7534859 Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse
05/19/2009US7534813 2-(4-substituted phenoxy)ethyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate orally coadministered with a decarboxylase inhibitor or a catechol O-methyltransferase inhibitor; improved bioavailability when administered in the colon; sustained release; sleep disorders; nervous system disorders
05/19/2009US7534803 Potassium and sodium channel moderators; brain disorders; strokes; multiple sclerosis
05/19/2009US7534800 pyrrolo[2,3-b]pyridine derivatives; treatment of neurodegenerative disorders related to apoptosis and/or inflammation; compound prepared by condensation, halogenation, hydrogenation, using silan protected drivatives
05/19/2009US7534799 Pyridomorphinans, thienomorphinans and use thereof
05/19/2009US7534790 Aminocyclohexyl ether compounds such as trans-[2-(4-morpholinyl)-1-(2-naphthenethoxy)]cyclohexane; arrhythmia, analgesia and local anesthesia
05/19/2009US7534786 Inhibition of tau-tau association
05/19/2009US7534784 ligands for Calcitonin gene related peptide; azepinone ligands; migranes; N-[5-(2,3-Difluorophenyl)-1-(2-methoxyethyl)-2-oxopiperidin-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide
05/19/2009US7534613 Methods of treating parkinson's disease using viral vectors
05/19/2009US7534450 Promoting metallothioneins by administering a copper-free nutrient supplement containing 50 - 150 mg of zinc, and further containing vitamin B6, pyridoxal-5'-phosphate, vitamin E, vitamin A, vitamin C, selenium, glutathione, taurine, and a mixture of amino acids
05/19/2009US7534440 Fusion molecules and methods for treatment of immune diseases
05/19/2009US7534439 Nucleic sequence and deduced protein sequence family with human endogenous retroviral motifs, and their uses
05/19/2009US7534425 As well as Paget's disease, neurological/neuromuscular diseases, nerve diseases, and/or psychotropic diseases; chloride channel modulators
05/19/2009CA2611072A1 Novel compounds and uses thereof
05/19/2009CA2521923C Substance exhibiting antidepressant property
05/19/2009CA2463947C Montelukast granule formulation
05/19/2009CA2441192C The use of lysine for the prevention or treatment of stress-induced diseases
05/19/2009CA2395969C Novel tetrahydropyridines, method for the preparation thereof and pharmaceutical compositions containing them
05/19/2009CA2367955C Abc1 polypeptide and methods and reagents for modulating cholesterol levels
05/19/2009CA2352564C Use of effectors of the central cholinergic nervous system
05/19/2009CA2352542C Method for producing medicaments from plant extracts, in a solid form of administration
05/19/2009CA2338651C Pyrrolo[2,1-b][1,3]benzothiazepines with atypical antipsychotic activity
05/19/2009CA2336634C Antiviral macrocyclic compounds
05/19/2009CA2317036C Novel optically active aminopentane derivatives
05/19/2009CA2292968C Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
05/19/2009CA2209167C Hydroxylamine derivatives useful for enhancing the molecular chaperon production and the preparation thereof
05/14/2009WO2009062118A2 Modulation of protein trafficking
05/14/2009WO2009061924A2 Aldh-2 inhibitors in the treatment of psychiatric disorders
05/14/2009WO2009061906A2 Treating protein misfolding diseases
05/14/2009WO2009061744A2 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
05/14/2009WO2009060835A1 Novel ubiquilin-binding small molecule
05/14/2009WO2009060609A1 Method for producing microcapsule using solid fat
05/14/2009WO2009060445A1 Synthetic sphingolipid analogs
05/14/2009WO2009060030A1 Heteroaryl-substituted 2-pyridinylmethylamine derivatives
05/14/2009WO2009059755A2 Novel neurturin conjugates for pharmaceutical use
05/14/2009WO2009059666A1 7-azaindole derivatives as selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
05/14/2009WO2009040083A3 Use of a peptide as a therapeutic agent
05/14/2009WO2009040047A3 Therapeutic uses of ghrelin and combinations with stresscopin
05/14/2009WO2009040033A3 Use of a peptide as a therapeutic agent
05/14/2009WO2009040019A3 Use of a peptide as a therapeutic agent
05/14/2009WO2009039986A3 Use of the peptide asn-asp-asp-cys-glu- leu-cys-val-asn-val-ala-cys-thr-gly-cys-leu alone or in combination with the peptide thr-thr-ser-gln-val- arg-pro-αrg as a therapeutic agent
05/14/2009WO2009033807A3 Therapeutic uses of b-type natriuretic peptide and human growth hormone 1-43
05/14/2009WO2009033804A3 Use of gamma- endorphin as a therapeutic agent
05/14/2009WO2009033803A3 Use of the pentapeptide drlds and gamma-endorphin as therapeutic agents
05/14/2009WO2009033799A3 Use of a peptide as a therapeutic agent
05/14/2009WO2009033754A8 Use of a peptide as a therapeutic agent
05/14/2009WO2009027601A3 Pyrazole 3,5 carboxylate derivatives preparation and therapeutic application thereof
05/14/2009WO2009021295A3 Inhibition of alpha synuclein toxicity
05/14/2009WO2009016069A4 Stable liquid pharmaceutical composition based on trazodone
05/14/2009WO2007059000A3 Modulation of angiogenesis by a-beta peptide fragments
05/14/2009US20090124700 Administering L-lysine-d-amphetamine or salts
05/14/2009US20090124698 Selective estrogen receptor modulator compositions and methods for treatment of disease
05/14/2009US20090124696 Abuse-resistant amphetamine prodrugs
05/14/2009US20090124686 Gsk-3 inhibitors
05/14/2009US20090124674 Method for treating congestive heart failure
05/14/2009US20090124673 Method for treating diabetic nephropathy
05/14/2009US20090124672 Aldh-2 inhibitors in the treatment of psychiatric disorders
05/14/2009US20090124666 Trpv1 antagonists
05/14/2009US20090124663 Novel n-phenyl-piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
05/14/2009US20090124662 Migrastatin analogs in the treatment of cancer
05/14/2009US20090124659 Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase and inhibitors
05/14/2009US20090124655 Heterocyclic derivatives as modulators of ion channels
05/14/2009US20090124651 Catecholamine derivatives and prodrugs thereof
05/14/2009US20090124649 Aza spiro alkane derivatives as inhibitors of metalloproteases
05/14/2009US20090124645 Novel Pyrimidine-2,4-Diamine Derivatives and their Use as Modulators of Small-Conductance Calcium-Activated Potassium Channels
05/14/2009US20090124630 N-[4-(2-methoxyphenyl)piperazin-1-yl)butyl]-3,4-dihydro-6-fluoro-2-naphthamide for treating neuropsychological disorder selected from Parkinson's disease, schizophrenia and depression; partial agonists or antagonists of the dopamine D3 receptor
05/14/2009US20090124627 Compositions for sleeping disorders
05/14/2009US20090124625 Novel alkynyl derivatives as modulators of metatropic glutamate receptors
05/14/2009US20090124614 Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders
05/14/2009US20090124613 Substituted Heterocyclic Ethers and Their Use in CNS Disorders
05/14/2009US20090124606 Composition for Treatment of Psychosis
05/14/2009US20090124605 Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use as Kinase Inhibitors
05/14/2009US20090124602 Kinase inhibitors
05/14/2009US20090124592 Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity
05/14/2009US20090124588 Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions
05/14/2009US20090124578 administering 3-(4'-Morpholin-4-ylmethyl-biphenyl-4-ylmethyl)-1-oxa-3-aza-spiro[4.5]decan-2-one, for the treatment of schizophrenia
05/14/2009US20090124564 Compositions and methods for regulating apoptosis
05/14/2009US20090124555 Use of histogranin and histogranin-like compounds as inhibitors of p2x7 receptor function and as anti-arthritic agents
05/14/2009US20090124548 Method of Using Fish Plasma Components to Inhibit Glial Scarring and Promote Functional Recovery in the Mammalian CNS
05/14/2009US20090124547 conjugated drug comprising nerve growth factor linked to a steroid; for tissue-targeted therapy; treating pain
05/14/2009US20090124543 Activity dependent neurotrophic factor iii (adnf iii)
05/14/2009US20090123974 Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
05/14/2009US20090123936 Conformationally abnormal forms of tau proteins and specific antibodies thereto
05/14/2009US20090123575 Blended Compositions for Treatment of Alzheimer's Disease and Other Amyloidoses
05/14/2009US20090123571 Method of treating men with testosterone supplement and 5alpha-reductase inhibitor
05/14/2009US20090123565 Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto
05/14/2009US20090123559 Medicine to Treat Drug Addiction and Preparation Method Thereof
05/14/2009US20090123554 Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
05/14/2009US20090123545 Rapid Onset and Short Term Modafinil Compositions and Methods of Use Thereof
05/14/2009US20090123535 Oral Controlled Release Formulation for Sedatives and Hypnotic Agents
05/14/2009US20090123531 Glutathione-based delivery system
05/14/2009US20090123528 Transdermal delivery of beneficial substances effected by a hostile biophysical environment
05/14/2009US20090123527 Method of inducing topical anesthesia and transdermal patch
05/14/2009US20090123498 Treatment of post-stroke muscle pain
05/14/2009US20090123497 Chromatographic method and system for purifying a botulinum toxin
1 ... 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 ... 1833